Page last updated: 2024-09-03

opc 3911 and cilomilast

opc 3911 has been researched along with cilomilast in 1 studies

Compound Research Comparison

Studies (opc 3911)	Trials (opc 3911)	Recent Studies (post-2010) (opc 3911)	Studies (cilomilast)	Trials (cilomilast)	Recent Studies (post-2010) (cilomilast)
16	0	0	162	13	42

Protein Interaction Comparison

Protein	Taxonomy	cilomilast (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.018
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.018
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	0.018
Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	0.018
cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	2.3453
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	Homo sapiens (human)	2.3453
cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	2.3453
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Rattus norvegicus (Norway rat)	0.113
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Rattus norvegicus (Norway rat)	0.113
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Rattus norvegicus (Norway rat)	0.1623
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)	0.3113
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	0.062
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Rattus norvegicus (Norway rat)	0.113
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)	2.3453
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Homo sapiens (human)	0.4623
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Homo sapiens (human)	0.818
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.4642
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)	4.259
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)	10
Beta-2 adrenergic receptor	Cavia porcellus (domestic guinea pig)	0.12
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A	Homo sapiens (human)	2.3453
cAMP-specific 3',5'-cyclic phosphodiesterase 7B	Homo sapiens (human)	2.3453
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)	2.3453

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Guan, Q; Montrose, DC; Quilley, J; Rajagopalan, S; Smith, CJ; Zhao, H	1

Other Studies

1 other study(ies) available for opc 3911 and cilomilast

Article	Year
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty. American journal of physiology. Heart and circulatory physiology, 2007, Volume: 292, Issue:6 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Milrinone; Nitriles; Phosphodiesterase Inhibitors; Phosphorylation; Quinolones; Rats; Rats, Sprague-Dawley; Tetrazoles; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents	2007

Article

Year

Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.

American journal of physiology. Heart and circulatory physiology, 2007, Volume: 292, Issue:6

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Milrinone; Nitriles; Phosphodiesterase Inhibitors; Phosphorylation; Quinolones; Rats; Rats, Sprague-Dawley; Tetrazoles; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents

2007